The Global Health Body Issues Warning Over Severe Shortage of Obesity Jabs
Fewer than 10% of individuals eligible to benefit from weight-loss injections such as Wegovy have access to them, caution the global health agency as it publishes its initial advice on the drugs.
Given over a billion individuals worldwide now obese, it is advocating for increased and just access to this class of drugs.
According to estimates, more than two billion will be living with obesity by 2030 unless action is taken.
"Our latest guidelines affirms that obesity is a long-term condition that can be treated with thorough and continuous support," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are major hurdles to widespread availability to the jabs that can aid individuals in losing significant body mass, says the body.
GLP-1 Therapy Shortage
Even under the present best projected case, the manufacturing of these medications would only suffice for about 100 million people – under 10% of those who need them, as stated by the WHO.
The guideline urges countries and companies to expand availability, by strategies including licensing agreements.
The intellectual property rights on a key compound – the main component of a leading brand – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Jabs Function
The injections imitate a biological compound to delay gastric emptying, curb appetite and increase feelings of fullness so users reduce food intake.
Patients usually see weight reduction within a few weeks of beginning the regular doses.
Evidence points to patients may regain a significant portion within a year of stopping the drug, as their normal hunger return.
Being overweight or obese increases your chance for experiencing medical conditions, such as diabetes, cardiovascular issues, brain attack, and specific cancers.
Excess weight impacts individuals in every country and was associated with millions of fatalities worldwide in 2024, as per the WHO.
